Brokers Suggest Investing in Teradyne (TER): Read This Before Placing a Bet

27.02.26 15:30 Uhr

Werte in diesem Artikel
Aktien

260,35 EUR -11,25 EUR -4,14%

Indizes

10.210,8 PKT -98,3 PKT -0,95%

6.582,7 PKT 7,4 PKT 0,11%

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Teradyne (TER) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Teradyne currently has an average brokerage recommendation (ABR) of 1.65, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 17 brokerage firms. An ABR of 1.65 approximates between Strong Buy and Buy.Of the 17 recommendations that derive the current ABR, 11 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 64.7% and 5.9% of all recommendations.Brokerage Recommendation Trends for TERCheck price target & stock forecast for Teradyne here>>>The ABR suggests buying Teradyne, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.ABR Should Not Be Confused With Zacks RankAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.Is TER a Good Investment?Looking at the earnings estimate revisions for Teradyne, the Zacks Consensus Estimate for the current year has increased 15.5% over the past month to $5.91.Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for Teradyne. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Therefore, the Buy-equivalent ABR for Teradyne may serve as a useful guide for investors.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teradyne, Inc. (TER): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Teradyne und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Quelle: Zacks

Nachrichten zu Teradyne Inc.

Analysen zu Teradyne Inc.

DatumRatingAnalyst
25.04.2019Teradyne Market PerformCowen and Company, LLC
25.10.2018Teradyne BuyCraig Hallum
26.07.2018Teradyne BuyNeedham & Company, LLC
26.07.2018Teradyne Market PerformCowen and Company, LLC
26.01.2018Teradyne BuyNeedham & Company, LLC
DatumRatingAnalyst
25.10.2018Teradyne BuyCraig Hallum
26.07.2018Teradyne BuyNeedham & Company, LLC
26.01.2018Teradyne BuyNeedham & Company, LLC
24.01.2018Teradyne BuyStifel, Nicolaus & Co., Inc.
05.07.2017Teradyne BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
25.04.2019Teradyne Market PerformCowen and Company, LLC
26.07.2018Teradyne Market PerformCowen and Company, LLC
21.11.2017Teradyne HoldDeutsche Bank AG
29.10.2015Teradyne Sector WeightPacific Crest Securities Inc.
11.06.2012Teradyne neutralUBS AG
DatumRatingAnalyst
30.07.2009Teradyne ErsteinschätzungMorgan Stanley
22.12.2008Teradyne underweightJP Morgan Chase & Co.
06.12.2005Update Teradyne Inc.: UnderperformGoldman Sachs
06.12.2005Teradyne underperformGoldman Sachs

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Teradyne Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen